Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 67
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT01266018 | Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer | ||
| NCT01689870 | Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma | ||
| NCT00142415 | Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer | ||
| NCT02334735 | A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence | ||
| NCT00292045 | Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer | ||
| NCT00145145 | Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma | ||
| NCT00520299 | Study of ADI-PEG 20 in Patients With Advanced Melanoma | ||
| NCT02425306 | Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma | ||
| NCT00003102 | Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer | ||
| NCT02659540 | Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma | ||
| NCT00142454 | NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting) | ||
| NCT00199862 | Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer | ||
| NCT00616941 | Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | ||
| NCT00299728 | NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors | ||
| NCT00199901 | Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma | ||
| NCT00112957 | Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | ||
| NCT00623831 | A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen | ||
| NCT00006046 | Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer | ||
| NCT00112229 | Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients | ||
| NCT02431559 | Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer | ||
| NCT03164772 | Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC | ||
| NCT00199797 | Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer | ||
| NCT01810016 | NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma | ||
| NCT01490047 | Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas | ||
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | ||
| NCT02336165 | Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma | ||
| NCT00518206 | Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma | ||
| NCT00070070 | Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas | ||
| NCT06002802 | Study on Infectious Mononucleosis in Munich | ||
| NCT00072410 | Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer | ||
| NCT00066729 | Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | ||
| NCT00006099 | Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer | ||
| NCT00291486 | Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer | ||
| NCT02735239 | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer | ||
| NCT04729543 | MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer | ||
| NCT00199875 | Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250 | ||
| NCT00112242 | Immunotherapy of Stage III/IV Melanoma Patients | ||
| NCT00291473 | Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers | ||
| NCT02716805 | Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant | ||
| NCT00140855 | A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma | ||
| NCT01131169 | Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions | ||
| NCT00291447 | 111In-ch806 in Patients With Advanced Tumours Expressing the 806 Antigen | ||
| NCT01220999 | A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer | ||
| NCT01380145 | MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation | ||
| NCT05190094 | Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies. | ||
| NCT00199849 | NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine | ||
| NCT01838200 | Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma | ||
| NCT00199836 | A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer. | ||
| NCT02046733 | Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease | ||
| NCT01498172 | BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients |
